Search details
1.
Multi-omic machine learning predictor of breast cancer therapy response.
Nature
; 601(7894): 623-629, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34875674
2.
Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial.
Lancet
; 402(10395): 54-61, 2023 07 01.
Article
in English
| MEDLINE | ID: mdl-37271152
3.
Digital pathology for reporting histopathology samples, including cancer screening samples - definitive evidence from a multisite study.
Histopathology
; 84(5): 847-862, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38233108
4.
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
Lancet Oncol
; 23(1): 149-160, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34902335
5.
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Lancet
; 393(10191): 2599-2612, 2019 06 29.
Article
in English
| MEDLINE | ID: mdl-31178152
6.
Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
BMC Cancer
; 18(1): 391, 2018 04 05.
Article
in English
| MEDLINE | ID: mdl-29621991
7.
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
Lancet Oncol
; 18(6): 755-769, 2017 06.
Article
in English
| MEDLINE | ID: mdl-28479233
8.
Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial.
Mod Pathol
; 30(8): 1069-1077, 2017 08.
Article
in English
| MEDLINE | ID: mdl-28548129
9.
Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.
Breast Cancer Res
; 18(1): 21, 2016 Feb 16.
Article
in English
| MEDLINE | ID: mdl-26882907
10.
Trastuzumab-associated cardiac events in the Persephone trial.
Br J Cancer
; 115(12): 1462-1470, 2016 Dec 06.
Article
in English
| MEDLINE | ID: mdl-27875516
11.
Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' reply.
Lancet
; 395(10223): 492-493, 2020 02 15.
Article
in English
| MEDLINE | ID: mdl-32061290
12.
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 16(6): 656-66, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-25975632
13.
Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean?
BMC Med
; 13: 234, 2015 Sep 22.
Article
in English
| MEDLINE | ID: mdl-26391216
14.
A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities.
BMC Med
; 13: 306, 2015 Dec 29.
Article
in English
| MEDLINE | ID: mdl-26715442
15.
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.
Lancet Oncol
; 15(2): 201-12, 2014 Feb.
Article
in English
| MEDLINE | ID: mdl-24360787
16.
Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial.
Int J Cancer
; 133(6): 1470-8, 2013 Sep 15.
Article
in English
| MEDLINE | ID: mdl-23483540
17.
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis.
Cancer Cell
; 3(4): 387-402, 2003 Apr.
Article
in English
| MEDLINE | ID: mdl-12726864
18.
Digital pathology: the effect of experience on visual search behavior.
J Med Imaging (Bellingham)
; 9(3): 035501, 2022 May.
Article
in English
| MEDLINE | ID: mdl-35572382
19.
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).
Lancet Oncol
; 11(3): 266-74, 2010 Mar.
Article
in English
| MEDLINE | ID: mdl-20079691
20.
Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.
Blood
; 112(9): 3807-17, 2008 Nov 01.
Article
in English
| MEDLINE | ID: mdl-18599795